Key facts
- It has raised $80.0M; the latest was Seed Round ($80.0M) in Jan 2026.
- Notable investors include DCVC, Alexandria Venture Investments, AIX Ventures, Modi Ventures, nVentures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Proxima (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Proxima (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Proxima (Drug Discovery)
Developer of precision-engineered bioreactor systems intended to enable sustainable protein production through cellular agriculture. The company designs and builds modular bioprocessing equipment with integrated control systems, scalable architecture, advanced monitoring capabilities and compatibility with diverse cell lines, offering automated nutrient delivery, real-time data analytics and optimized growth environments, enabling cultivated meat and alternative protein producers to achieve consistent yields, reduce operational complexity and accelerate commercialization while meeting stringent food safety and regulatory standards.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Website
- proximabio.com/
- Ownership
- Privately Held (backing)
Proxima (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proxima (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proxima (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.